Vitrolife: Conference call interim report
Vitrolife invites stakeholders to a conference call on April 22, 2022, at 10:00 a.m. CET for the presentation of its interim report for January-March 2022. Dial-in details are provided for Sweden and internationally, with a conference ID of 6938009. The interim report will be released at 8:00 a.m. CET on the same day, and presentation materials will be accessible on the company’s website. A recorded version of the call will be available for seven days post-event. Contact for inquiries is Patrik Tolf, CFO.
- Scheduled conference call for Q1 2022 report indicates ongoing communication with investors.
- None.
Insights
Analyzing...
GÖTEBORG, Sweden , April 8, 2022 /PRNewswire/ -- Invitation to attend Vitrolife's conference call regarding presentation of the interim report January - March 2022. The presentation will be held in English.
Time: Friday 22 April, 2022 at 10.00 a.m. CET.
Registration can preferably be done 10-15 minutes before the conference start time on:
Sweden dial in number: +46 (0)8 506 921 69
International dial in number: +44 (0) 2030 095709
Conference name: Vitrolife, conference ID: 6938009
Event Passcode: 6938009
Vitrolife participants:
Thomas Axelsson, CEO
Patrik Tolf, CFO
The press release for Vitrolife's interim report will be released at 8.00 CET on the same day.
Before the conference call, presentation material will be available at the company web page, https://www.vitrolife.com/investors/Presentations/
A recorded version of the telephone conference will be available for seven days on number +44 (0) 333 300 9785 (International), access code 6938009.
Contact:
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/vitrolife-ab--publ-/r/conference-call-interim-report,c3542617
The following files are available for download:
Conference call Q1 2022 |
View original content:https://www.prnewswire.com/news-releases/vitrolife-conference-call-interim-report-301520719.html
SOURCE Vitrolife AB (publ)